Did you mean bitopertin of ro 493838 of r 18 of ビトペルチン?
Displaying drugs 2876 - 2900 of 9630 in total
Raxibacumab
Raxibacumab is a human IgG1λ monoclonal antibody that binds the protective antigen (PA) component of B. anthracis toxin. Raxibacumab has a molecular weight of approximately 146 kilodaltons. Raxibacumab is produced by recombinant DNA technology in a murine cell expression system. FDA approved on December 14, 2012.
Approved
Matched Description: … Raxibacumab has a molecular weight of approximately 146 kilodaltons. ... Raxibacumab is a human IgG1λ monoclonal antibody that binds the protective antigen (PA) component of …
Ravulizumab
Ravulizumab is a potent and selective complement 5 (C5) inhibitor. It is a humanized monoclonal IgG2/4 kappa antibody produced in Chinese hamster ovary (CHO) cells. Ravulizumab was engineered from eculizumab, another complement inhibitor, to increase the duration of action and reduce the frequency of drug administration. It works by blocking...
Approved
Investigational
Matched Description: … action and reduce the frequency of drug administration. ... Ravulizumab was engineered from [eculizumab], another complement inhibitor, to increase the duration of ... [L39690,L39700] Ravulizumab is currently being investigated for the treatment of Coronavirus disease …
Revefenacin
Revefenacin is a novel biphenyl carbamate tertiary amine agent that belongs to the family of the long-acting muscarinic antagonists (LAMA). The labile primary amide in the structure produces a "soft-drug" site that allows rapid systemic clearance and minimizing of the systemically mediated adverse reactions. The LAMA group falls into a...
Approved
Investigational
Matched Description: … Revefenacin is a novel biphenyl carbamate tertiary amine agent that belongs to the family of the long-acting ... LAMA group falls into a parent category known as long-acting inhaled bronchodilators and this type of ... amide in the structure produces a "soft-drug" site that allows rapid systemic clearance and minimizing of …
Rasburicase
Rasburicase is a recombinant urate-oxidase enzyme produced by a genetically modified Saccharomyces cerevisiae strain. The cDNA coding for rasburicase was cloned from a strain of Aspergillus flavus.
Approved
Investigational
Matched Description: … The cDNA coding for rasburicase was cloned from a strain of _Aspergillus flavus_. …
Retapamulin
Retapamulin, marketed by GlaxoSmithKline as the ointment Altabax, is an antibiotic for skin infections like impetigo. It was approved by the FDA in April 2007.
Approved
Aminohippuric acid
The glycine amide of 4-aminobenzoic acid. Its sodium salt is used as a diagnostic aid to measure effective renal plasma flow (ERPF) and excretory capacity. [PubChem]
Approved
Investigational
Matched Description: … The glycine amide of 4-aminobenzoic acid. …
Risankizumab
Risankizumab is a fully humanized IgG1 monoclonal antibody (mAb) directed against interleukin 23 (IL-23). It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019. Risankizumab is used to treat plaque psoriasis, psoriatic arthritis, and Crohn's disease.[L39885,L44191,L44231] Risankizumab...
Approved
Investigational
Calcium carbimide
Calcium carbimide, sold as the citrate salt, is an alcohol-sensitizing agent. Its effects are similar to the drug disulfiram (Antabuse) in that it interferes with the normal metabolism of alcohol by preventing the breakdown of the metabolic product acetaldehyde. Calcium carbimide was conceived as an alternative for the treatment of...
Approved
Withdrawn
Matched Description: … alcohol by preventing the breakdown of the metabolic product acetaldehyde. ... The current status of calcium carbimide is cancelled post marketing.[L1113] ... effects are similar to the drug disulfiram (Antabuse) in that it interferes with the normal metabolism of …
Fluoride ion F-18
Sodium Fluoride F 18 Injection is a positron emitting radiopharmaceutical, no-carrier added. It contains radioactive fluoride F 18 that is used for diagnostic purposes in conjunction with positron emission tomography (PET) imaging and is administered by intravenous injection. Its primary indication is for bone imaging. Increased deposition around joints can...
Approved
Retifanlimab
Retifanlimab is a humanized IgG4 kappa monoclonal antibody that binds to the programmed death receptor-1 (PD-1), blocking PD-1 interaction with its ligands, programmed death-ligand 1 (PD-L1) and programmed death-ligand 2 (PD-L2). By blocking the PD-1/PD-L1/2 pathway, retifanlimab potentiates T-cell activity and boosts the immune response against cancer cells. Other monoclonal...
Approved
Investigational
Matched Description: … for the treatment of squamous carcinoma of the anal canal. ... [L45603,L45613] The use of retifanlimab in combination with other oncology drugs for the treatment of ... 2023, the FDA granted accelerated approval to retifanlimab for a different indication, the treatment of …
Benzoin resin
Benzoin resin is a balsamic resin obtained from the bark of several species of trees in the genus Styrax. There are two common kinds of benzoin, benzoin Siam and benzoin Sumatra, that are obtained from different species of the Styrax tree. While benzoin resin is used as a common ingredient...
Approved
Matched Description: … property of tape. ... species of the _Styrax_ tree. ... Benzoin resin is a balsamic resin obtained from the bark of several species of trees in the genus _Styrax …
Racephedrine
Approved
Experimental
Polysorbate 80
Polysorbate, a substance formulated by the reaction of sorbitan fatty acid ester (a nonionic surfactant) with ethylene oxide, is used in many foreign countries, including the U.S. and the EU, where it acts as an emulsifier, a solubilizer in many foods, including bread, cake mix, salad dressing, shortening oil and...
Approved
Matched Description: … Polysorbate, a substance formulated by the reaction of sorbitan fatty acid ester (a nonionic surfactant ... substance that would not normally dissolve in a particular solution is able to dissolve with the use of ... [L1852]
A solubilizing agent acts as a surfactant and increases the solubility of one agent in another …
Phendimetrazine
Phendimetrazine is a weight loss medication. Phendimetrazine is chemically related to amphetamines and is a Schedule III drug under the Convention on Psychotropic Substances and in the US since 1970.
Approved
Illicit
Promazine
A phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. It is currently not approved for use in the United States.
Approved
Vet approved
Matched Description: … It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. …
Matched Categories: … Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome …
Matched Categories: … Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome …
Modafinil
Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. The prexin neuron activation is associated...
Approved
Investigational
Matched Description: … Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides ... used in the treatment of narcolepsy. ... Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants …
Matched Categories: … Metabolic Side Effects of Drugs and Substances …
Matched Categories: … Metabolic Side Effects of Drugs and Substances …
Selegiline
A selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy. It also may be given with levodopa upon onset of disability. (From AMA Drug Evaluations Annual,...
Approved
Investigational
Vet approved
Matched Description: … A selective, irreversible inhibitor of Type B monoamine oxidase. ... It also may be given with levodopa upon onset of disability. ... It may slow progression of the clinical disease and delay the requirement for levodopa therapy. …
Matched Categories: … Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome …
Matched Categories: … Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome …
Sertraline
Sertraline is a popular antidepressant medication commonly known as a selective serotonin reuptake inhibitor (SSRI), and is similar to drugs such as Citalopram and Fluoxetine. Despite marked structural differences between compounds in this drug class, SSRIs exert similar pharmacological effects.
Several weeks of therapy with sertraline may be required before...
Approved
Matched Description: … cause high levels of drowsiness, dizziness, blurred vision, and other undesirable effects. ... Several weeks of therapy with sertraline may be required before beneficial effects are noticed. ... Sertraline displays enhanced safety or tolerability than other classes of antidepressants, which frequently …
Matched Categories: … Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome …
Matched Categories: … Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome …
Selumetinib
Activation of the Raf-MEK-ERK signalling pathway is known to be implemented in several types of malignancies; thus, mitogen-activated protein kinase kinase (MEK) inhibitors such as selumetinib are important tools that can target the problematic overactivity of this pathway. Results from clinical trials investigating earlier developed MEK inhibitors were underwhelming. However,...
Approved
Investigational
Matched Description: … Activation of the Raf-MEK-ERK signalling pathway is known to be implemented in several types of malignancies ... various types of tumours in Phase II trials. ... NF-1 is considered rare, with an estimated incidence of 1/3000 individuals. …
Metformin
Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.[L12207,A176173]
Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "insulin sensitizer", leading to a decrease in insulin...
Approved
Matched Description: … Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of ... [A176173] Another well-known benefit of this drug is modest weight loss, making it an effective choice ... insulin sensitizer", leading to a decrease in insulin resistance and a clinically significant reduction of …
Matched Mixtures name: … SIPTATINMET R …
Matched Products: … Metformin Hydrochloride E/r …
Matched Mixtures name: … SIPTATINMET R …
Matched Products: … Metformin Hydrochloride E/r …
Anthralin
Anthralin (1,8‐dihydroxy‐9anthrone, dithranol) is an older anti-psoriatic agent that was first synthesized as a derivative of chrysarobin, obtained from the araroba tree in Brazil over 100 years ago. Adverse effects of anthralin include irritation and discoloration of the skin .
This specific property of the molecule inspired workers to study...
Approved
Matched Description: … Adverse effects of anthralin include irritation and discoloration of the skin [A27277]. ... This specific property of the molecule inspired workers to study details of its pharmacology. ... It is a main active ingredient in topical skin formulations for the treatment of psoriasis. …
Prucalopride
Prucalopride is a dihydrobenzofurancarboxamide derivative from the benzofurane family that selectively stimulates 5-HT4 receptors and thus, it presents enterokinetic properties. The high selectivity of prucalopride allowed further development as it prevented the cardiac adverse reactions observed due to non-target effects of precedent therapies. Prucalopride was developed by Shire Development LLC...
Approved
Matched Description: … adverse reactions observed due to non-target effects of precedent therapies. ... [A37348] The high selectivity of prucalopride allowed further development as it prevented the cardiac …
Vadadustat
One of the most common symptoms of advanced renal disease is anemia, caused primarily by the inability of the kidney to respond to anemic conditions with a corresponding increase in erythropoietin (EPO) production. The treatment of anemia associated with chronic kidney disease (CKD) has traditionally involved the administration of exogenous...
Approved
Investigational
Matched Description: … One of the most common symptoms of advanced renal disease is anemia, caused primarily by the inability ... These transcription factors serve a multitude of roles, including the stimulation of erythropoiesis. ... of CKD, and increases in overall mortality. …
Antihemophilic factor, human recombinant
Human recombinant antihemophilic factor (AHF) or Factor VIII, 2332 residues, glycosylated, produced by CHO cells
Approved
Investigational
Displaying drugs 2876 - 2900 of 9630 in total